Adverse effects to the Pfizer-BioNTech vaccine in staff of a tertiary hospital
DOI:
https://doi.org/10.30827/ars.v66i1.31090Keywords:
Vaccines, COVID-19, Adverse reactions and side events related to drugs, PharmacovigilanceAbstract
Introduction: One of the vaccines to combat the COVID-19 coronavirus pandemic was the RNA-messenger vaccine developed by Pfizer-BioNTech. In early 2021, hospital workers in Mexico received two doses of this vaccine. The objective of this study was to determine the frequency of adverse events (AE) to the Pfizer-BioNTech vaccine in a cohort of staff at a tertiary hospital in southeastern Mexico and to identify factors associated with the development of AE.
Method: Cross-sectional, observational and descriptive study carried out in the staff of a tertiary hospital. AE’s were identified through active surveillance and telephone follow-up between the second and fifteenth day after the first and second immunization. Demographic and clinical data were captured in an electronic database.
Results: A total of 1033 subjects were surveyed, with a mean age of 39.04±9.20 years and 53.4% female. 94.5% of subjects experienced at least one AE after administration of the Pfizer-BioNTech vaccine. A total of 2805 AEs were detected (1360 first dose and 1445 second dose). The most frequently reported AEs at both doses were application site pain, headache, fatigue and pyrexia.
Conclusions: The frequency of AEs in the present study was consistent with previous reports for the Pfizer-BioNTech vaccine. AEs were mild and transient showing good tolerability. Female sex, having a chronic-degenerative disease and a history of allergy were significantly associated with the presence of any AE.
Downloads
References
Polack FP, Thomas SJ, Kitchin N, et al. Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27): 2603-2615. Doi: 10.1056/NEJMoa2034577.
Organización Mundial de la Salud. WHO sage roadmap for prioritizing use of covid-19 vaccines. [Online]. Disponible en: https://cdn.who.int/media/docs/default-source/immunization/sage/2022/january/who-2019-ncov-vaccines-sage-prioritization-2022.1-eng.pdf?sfvrsn=97633cf_5 [Consultada a 15 Mayo 2024].
Gobierno de México. Política nacional rectora de vacunación contra el SARS-CoV-2 para la prevención de la COVID-19 en México. Documento rector. [Online]. Disponible en: https://coronavirus.gob.mx/wp-content/uploads/2021/04/28Abr2021_13h00_PNVx_COVID_19.pdf [Consultada a 15 Mayo 2024].
Ministerio de Salud del Gobierno de Chile. Ficha vacuna contra SARS-CoV-2 vacuna bnt162b2 Laboratorio Pfizer-Biontech. [Ficha técnica Online]. Disponible en: https://www.minsal.cl/wp-content/uploads/2021/01/Ficha-Vacuna-Pfizer-BioNTech.pdf [Consultada a 8 Abril 2024].
Palomo-Palomo C, Guerra-Estévez D, Parrado-González A, Estaire-Gutiérrez J, Reyes-Malia M, Romero-Alonso MM. Reactogenicidad de la vacuna de ARNm BNT162b2 (Pfizer-BioNTech) frente a COVID-19 en trabajadores de un hospital de tercer nivel. Farm Hosp. 2022; 46(3): 152–156. Doi: 10.7399/fh.13047
Llerena CA, Aucanshala Shigla EV. Adverse effects post vaccination against COVID-19 in adolescents. Sal Cien Tec. 2023; 3: 372. Doi:10.56294/saludcyt2023372
Willame, C, Dodd C, Durán CE, et al. Background rates of 41 adverse events of special interest for COVID-19 vaccines in 10 European healthcare databases - an ACCESS cohort study. Vaccine. 2023; 41(1): 251–262. Doi:10.1016/j.vaccine.2022.11.031
Amancio-Chassin O, Pharmacovigilance in the vaccination program against coronavirus disease 19. Rev Med Hosp Gen Mex. 2021; 84(3): 92-95. Doi: 10.24875/HGMX.M21000041
Martínez-Roa AC, Labra-Rubio L, Landeros-Navarro IY. Incidencia de efectos adversos de la vacuna contra COVID-19 Pfizer/BioNTech: estudio de cohorte retrospectivo. Rev Med Inst Mex Seguro Soc. 2023; 18;61(S-2): S114-S119.
Pérez-Nieto OR, Alonso-Bello CD, Deloya-Tomas E, et al. Adverse effects associated with the first dose of the Pfizer–BioNTech COVID-19 vaccine in healthcare workers from Mexico: a case serie from passive surveillance. COVID. 2023; 3(8): 1209–1219. Doi:10.3390/covid3080085.
Yun IS, Koo MJ, Park EH, et al. A comparison of active surveillance programs including a spontaneous reporting model for pharmacovigilance of adverse drug events in a hospital. Korean J Intern Med. 2012; 27: 443-450. Doi: 10.3904/kjim.2012.27.4.443.
Pfizer. Hoja informativa para proveedores de la salud que administren la vacuna (proveedores de vacunación). [Ficha técnica Online]. Disponible en: http://labeling.pfizer.com/ShowLabeling.aspx?id=15155 [Consultado a 28 Abril 2024].
Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA. 2021; 325(21):2201-2202. Doi: 10.1001/jama.2021.5374.
Saita M, Yan Y, Ito K, Sasano H, Seyama K, Naito T. Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers in Japan. J Infect Chemother. 2022; 28(1): 116-119. Doi:10.1016/j.jiac.2021.09.009
Hernández R, Villareal E, Galicia L, Vargas E, Margain. Diferencia de la incidencia de los efectos adversos, entre la primera y la segunda dosis de la vacuna Pfizer/Biontech en el personal de salud. Rev Asoc Med Bahía Blanca. 2022; 32(1): 13-19.
Filippatos F, Tatsi EB, Dellis C, Dessypris N, Syriopoulou V, Michos A. Association of clinical and epidemiological characteristics with COVID-19 BNT162b2 mRNA vaccine short-term adverse reactions in healthcare workers. Hum Vaccin Immunother. 2021;17(12):4755-4760. Doi:10.1080/21645515.2021.1985356
Eseverri JL, Ranea S, Marin A. Reacciones adversas a vacunas [Adverse reactions to vaccines]. Allergol Immunopathol (Madr). 2003;31(3):125-38. Spanish. doi: 10.1016/s0301-0546(03)79278-7.
Ebinger JE, Fert-Bober J, Printsev I, et al. Prior COVID-19 Infection and Antibody Response to Single Versus Double Dose mRNA SARS-CoV-2 Vaccination. medRxiv [Preprint]. 2021 Feb 26: 2021.02.23.21252230. Doi: 10.1101/2021.02.23.21252230.
Prendecki M, Clarke C, Brown J, et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021; 397(10280): 1178-1181. Doi: 10.1016/S0140-6736(21)00502-X..
Ripabelli G, Tamburro M, Buccieri N, et al. Active surveillance of adverse events in healthcare workers recipients after vaccination with COVID-19 BNT162b2 vaccine (Pfizer-BioNTech, Comirnaty): a cross-sectional study. J Community Health. 2022; 47; 211-225. Doi: 10.1007/s10900-021-01039-3
Maruyama A, Sawa T, Teramukai S, Katoh N. Adverse reactions to the first and second doses of Pfizer-BioNTech COVID-19 vaccine among healthcare workers. J Infect Chemother. 2022; 28(7): 934-942. doi: 10.1016/j.jiac.2022.03.015.
Chen PY, Wu BJ, Su MC, et al. Risk factors and incidence rates of self-reported short-term adverse events of COVID-19 vaccine booster dose. Vaccines (Basel). 2022; 10; 1115. Doi: 10.3390/vaccines10071115
Moncunill G, Aguilar R, Ribes M, et al. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers. EBioMedicine. 2022; 75: 103805. Doi: 10.1016/j.ebiom.2021.103805.
Abukhalil AD, Shatat SS, Abushehadeh RR, Al-Shami N, Naseef HA, Rabba A. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community. BMC Infect Dis. 2023; 23(1): 5. Doi: 10.1186/s12879-022-07974-3
Suehiro M, Okubo S, Nakajima K, et al. Adverse events following COVID-19 vaccination in young Japanese people: a case-control study of the risk of systemic adverse events by a questionnaire survey. Arch Clin Biom Res. 2021; 6: 9–29. Doi: 10.26502/acbr.50170222
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Mario Alberto Ramírez Camacho, Abraham Arcos-Díaz, Darwin Stalin Torres-Erazo, Kyra Angélica Argáez-Ojeda, Patricia del Carmen Marín-Alvarado, Julio César Lara-Riegos
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The articles, which are published in this journal, are subject to the following terms in relation to the rights of patrimonial or exploitation:
- The authors will keep their copyright and guarantee to the journal the right of first publication of their work, which will be distributed with a Creative Commons BY-NC-SA 4.0 license that allows third parties to reuse the work whenever its author, quote the original source and do not make commercial use of it.
b. The authors may adopt other non-exclusive licensing agreements for the distribution of the published version of the work (e.g., deposit it in an institutional telematic file or publish it in a monographic volume) provided that the original source of its publication is indicated.
c. Authors are allowed and advised to disseminate their work through the Internet (e.g. in institutional repositories or on their website) before and during the submission process, which can produce interesting exchanges and increase citations of the published work. (See The effect of open access).
